Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19? JAMANetworkOpen erasmusmcintl UvA_Amsterdam LUMC_Leiden SARSCoV2 COVID19 coronavirus covid antibodies
By Tarun Sai LomteJul 11 2023Reviewed by Danielle Ellis, B.Sc. A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies as pre-exposure prophylaxis for coronavirus disease 2019 .
About the study In the present study, researchers developed a decision analytic model to examine short-term health outcomes, the cost-effectiveness of mAb PrEP, and healthcare utilization costs among individuals at a high risk of severe COVID-19. The model used data from an ongoing, prospective, multi-center TURN-COVID study on anti-SARS-CoV-2 agents, including mAbs.
Findings The study included 636 COVID-19 patients; most individuals had an elevated risk of severe illness. About 137 patients had a body mass index > 30 kg/m2, 60 had hematological malignant neoplasm, 152 used immunosuppressants, and 108 underwent transplantation. Overall, 18% of COVID-19 patients were admitted to the intensive care unit , and 61% required oxygen therapy.
The model estimated 4,000-18,000 new infections per 100,000 individuals over 90 days among PrEP-eligible people, depending upon low or high probability of infection. High infection probability and low drug price would result in cost-saving per death averted at a minimum efficacy of 75%. However, low infection probability increased costs per death averted. With the high price of the drug , costs per death averted ranged between $1.1 million and $3.3 million, depending upon PrEP effectiveness.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
The causative role of age-associated pre-existing senescent cells on COVID-19 severityThe causative role of age-associated pre-existing senescent cells on COVID-19 severity NatureAging aging covid COVID19 SARSCov2 senescentcells lungs
Lire la suite »
Alarming pediatric hospital admissions linked to COVID-19 in EnglandMost SARS-CoV-2 associated hospital admissions in children and adolescents in England were due to SARS-CoV-2 or SARS-CoV-2 was a contributory factor. These results should inform future public health initiatives and research.
Lire la suite »
Prolonged T-cell response during severe COVID-19 does not contribute to long COVIDPersistent immune activation and elevated cytokine levels were observed in patients with severe COVID-19, even months after recovery. However, the correlation between immune activation and long COVID symptoms appeared to be independent, suggesting other factors influencing disease severity.
Lire la suite »
The vital role of smartphone apps during the COVID-19 pandemicAt the start of the coronavirus disease 2019 (COVID-19) pandemic, analog techniques like nasopharyngeal swab specimens for polymerase chain reaction (PCR) testing were prominent. The widespread use of nonpharmaceutical interventions (NPIs) such as facemasks and social distancing was reminiscent of the influenza outbreak in 1918.
Lire la suite »
Covid inquiry: NI chief medical officer to give evidenceNorthern Ireland's chief medical officer, Sir Michael McBride, will give evidence to the UK Covid-19 inquiry later
Lire la suite »
Covid-19 inquiry still waiting for Boris Johnson phone messages\n\t\t\tKeep abreast of significant corporate, financial and political developments around the world.\n\t\t\tStay informed and spot emerging risks and opportunities with independent global reporting, expert\n\t\t\tcommentary and analysis you can trust.\n\t\t
Lire la suite »